Laura A Williams
CIK 1869194 · View on SEC EDGAR ↗
First SEC filing: June 23, 2022 · Latest: June 23, 2022
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 18, 2026 | ARDX | S 10b5-1 | 81,898 | $5.99 | $490,569 | 378,195 Direct | -17.80% | Disposed | -33.9% (price as of 2026-08-21) |
| May 23, 2023 | ARDX | S | 2,583 | $3.65 | $9,428 | 319,430 Direct | -0.80% | Disposed | 8.5% (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 18, 2026 | ARDX | Stock Option (Right to Buy) | Common Stock (31,000) | $0.99 | Jan. 6, 2032 | 31,000 | Disposed |
| June 2, 2022 | ELVN | Stock Option (right to buy) | Common Stock (8,500) | $1.07 | June 1, 2032 | 8,500 | Acquired |
| June 29, 2021 | ELVN | Stock Options (Right to Buy) | Common Stock (15,457) | $8.12 | June 28, 2031 | 15,457 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 3 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
ARDX
M.D., M.P.H. Chief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $522,720 | — | $1,042,625 | $1,045,630 | $216,406 | — | — | $2,827,381 |
| 2023 | $483,600 | $181,210 | $214,500 | $748,121 | — | — | — | $1,627,431 |
| 2022 | $465,000 | $250,000 | $39,600 | $141,811 | $158,800 | — | — | $1,055,211 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.